Slc6a14 and Slc38a5 drive the glutaminolysis and serine–Glycine–One-Carbon pathways in cancer
T Sniegowski, K Korac, YD Bhutia, V Ganapathy - Pharmaceuticals, 2021 - mdpi.com
The glutaminolysis and serine–glycine–one-carbon pathways represent metabolic reactions
that are reprogramed and upregulated in cancer; these pathways are involved in supporting …
that are reprogramed and upregulated in cancer; these pathways are involved in supporting …
Fatty pancreas-centered metabolic basis of pancreatic adenocarcinoma: From obesity, diabetes and pancreatitis to oncogenesis
ML Chang - Biomedicines, 2022 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer, and it is
currently the third most common cause of cancer death in the USA Progress in the fight …
currently the third most common cause of cancer death in the USA Progress in the fight …
Multiplex stimulated Raman scattering imaging cytometry reveals lipid-rich protrusions in cancer cells under stress condition
In situ measurement of cellular metabolites is still a challenge in biology. Conventional
methods, such as mass spectrometry or fluorescence microscopy, would either destroy the …
methods, such as mass spectrometry or fluorescence microscopy, would either destroy the …
Nutrient restriction-activated Fra-2 promotes tumor progression via IGF1R in miR-15a downmodulated pancreatic ductal adenocarcinoma
GL Rampioni Vinciguerra, M Capece… - … and Targeted Therapy, 2024 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, characterized by an intense
desmoplastic reaction that compresses blood vessels and limits nutrient supplies. PDAC …
desmoplastic reaction that compresses blood vessels and limits nutrient supplies. PDAC …
Tumor microenvironment features and chemoresistance in pancreatic ductal adenocarcinoma: Insights into targeting physicochemical barriers and metabolism as …
TMA Carvalho, D Di Molfetta, MR Greco, T Koltai… - Cancers, 2021 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor
prognosis. The lack of early diagnosis and the absence of suitable biomarkers coupled with …
prognosis. The lack of early diagnosis and the absence of suitable biomarkers coupled with …
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer
Objective Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with limited
therapeutic options. However, metabolic adaptation to the harsh PDAC environment can …
therapeutic options. However, metabolic adaptation to the harsh PDAC environment can …
Tumor-suppressive and immune-stimulating roles of cholesterol 25-hydroxylase in pancreatic cancer cells
Cholesterol dependence is an essential characteristic of pancreatic ductal adenocarcinoma
(PDAC). Cholesterol 25-hydroxylase (CH25H) catalyzes monooxygenation of cholesterol …
(PDAC). Cholesterol 25-hydroxylase (CH25H) catalyzes monooxygenation of cholesterol …
Targeting aberrant amino acid metabolism for pancreatic cancer therapy: Opportunities for nanoparticles
X Zang, K Lei, J Wang, R Gong, C Gao, Z **g… - Chemical Engineering …, 2024 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies with
insidious initiation and early metastasis. The autonomous reprogramming of amino acid …
insidious initiation and early metastasis. The autonomous reprogramming of amino acid …
Stellate cells aid growth-permissive metabolic reprogramming and promote gemcitabine chemoresistance in pancreatic cancer
M Amrutkar, IP Gladhaug - Cancers, 2021 - mdpi.com
Simple Summary The great majority, more than 90%, of patients with pancreatic ductal
adenocarcinoma (PDAC) die within less than five years after detection of the disease …
adenocarcinoma (PDAC) die within less than five years after detection of the disease …
[HTML][HTML] Metabolic rewiring by loss of Sirt5 promotes Kras-induced pancreatic cancer progression
Background & Aims SIRT5 plays pleiotropic roles via post-translational modifications,
serving as a tumor suppressor, or an oncogene, in different tumors. However, the role SIRT5 …
serving as a tumor suppressor, or an oncogene, in different tumors. However, the role SIRT5 …